Meeting
2013 ASCO Annual Meeting
Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma or progressive secondary brain tumor.
Authors
James D. Peyton
Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN
James D. Peyton , Howard A. Burris III, Jeffrey A. Bacha , Dennis Brown , William J. Garner , Richard Stephen Schwartz , Kent C. Shih
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01478178
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2093)
DOI
10.1200/jco.2013.31.15_suppl.2093
Abstract #
2093
Poster Bd #
8A
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma.
First Author: Kent C. Shih
Poster
2014 ASCO Annual Meeting
Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioblastoma multiforme (GBM).
First Author: Kent C. Shih
Poster
2016 ASCO Annual Meeting
Phase I/II study of VAL-083 in patients with recurrent glioblastoma.
First Author: Kent C. Shih
Poster
2014 ASCO Annual Meeting
Phase IB trial of carboxyamidotriazole orotate (CTO) and temozolomide for recurrent malignant glioma (MG): A novel mechanism for modulation of multiple oncogenic pathways.
First Author: Antonio Marcilio Padula Omuro